Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-PRIDE: open-label pridopidine extension study in Huntington's disease
NL-OMON44008Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pridopidine in Huntington disease (HD), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Adverse events, Vital signs assessments and 8 more. Started Feb 2016; status: active, not recruiting.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON44008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44008.